

February 26, 2025  
Taiho Pharmaceutical Co., Ltd.  
Otsuka Holdings Co., Ltd.

**Solar Power Generation Facility Launched  
at Taiho Pharmaceutical's Kitajima Plant  
to Accelerate Carbon Neutrality Initiatives**

Taiho Pharmaceutical Co., Ltd. announced today that a new solar power generation facility has been completed at its Kitajima Plant in Tokushima Prefecture, Japan. The facility went into operation in February 2025.



Solar power generation facility at Kitajima Plant




Image of Kitajima Plant premises

Building this solar power generation facility is the part of the Otsuka group's integrated energy management which includes Taiho Pharmaceutical.<sup>\*1</sup> It is the largest solar power generation such facility in Japan within the Otsuka group. The facility is expected to generate approximately 4,400 MWh annually, reducing 1,880 tons of CO<sub>2</sub> emissions annually.<sup>\*2</sup>

This initiative aligns with Taiho Pharmaceutical's efforts to achieve carbon neutrality, under one of the Otsuka group's material issues, "Promote Positive Impact on Global Environment." Taiho Pharmaceutical has already adopted carbon-neutral electricity across all of its four plants<sup>\*3</sup> and two research centers,<sup>\*4</sup> and all of its office divisions are using Green Power Certificates.<sup>\*5</sup> The introduction of this solar power generation facility will further accelerate the company's carbon neutrality initiatives.

Taiho Pharmaceutical will continue to promote initiatives aiming to reduce its environmental impact, contributing to the realization of a sustainable society.

## Solar Power Generation Facility at Kitajima Plant

Operations commence	February 2025
Number of solar panels	6,336 panels
Estimated annual power generation	4,382 MWh
Estimated CO <sub>2</sub> emissions reduction (annual)	1,880 tons
Percentage reduction in total CO <sub>2</sub> emissions for the Kitajima Plant as a result of carbon-neutral electricity adoption and onsite solar power generation	53%

\*1 The management is to centralize energy management for group companies in Japan, procure renewable energy in bulk, generate it internally, and supply it to each business site.

\*2 Calculated using alternative values (based on emission factor by electricity providers for submission in FY2024)

\*3 Kitajima Plant, Tokushima Plant, Saitama Plant, and Inuyama Plant

\*4 Tsukuba area and Tokushima area

\*5 A mechanism whereby the environmental added value of electricity generated from renewable energy sources (green power) is certified by a third-party certification body. Based on this certification, the issuing entity provides Green Power Certificates to the power producer, who can then sell them to energy users.

### Kitajima Plant

The Kitajima Plant was completed in 2013 to serve as a global production base for anticancer drugs. In 2016, a new clinical trial drug manufacturing facility was added, seeking to expand manufacturing capabilities in line with the anticipated future growth of Taiho Pharmaceutical's global business.

### Main Initiatives for CO<sub>2</sub> Emissions Reduction

✓ Adoption of carbon-neutral electricity at all four plants and two research centers in Japan

As of September 2021, all power purchased for production and research activities in Japan is carbon-neutral electricity generated from renewable energy sources.

✓ Utilization of Green Power Certificates

Since 2021, all office divisions of the five Otsuka group companies,<sup>\*6</sup> including Taiho Pharmaceutical, have been purchasing Green Power Certificates, marking a transition of their entire annual electricity consumption (12.5 million kWh) to green energy.

\*6 Taiho Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Otsuka Chemical Co., Ltd., and Otsuka Foods Co., Ltd.

## Otsuka Group Initiatives for Carbon Neutrality

Under the 2050 Environmental Vision “Net Zero,” the Otsuka group is committed to reducing the total environmental impact of its business activities to zero. “Promote Positive Impact on Global Environment” is identified as one of the group’s material issues. To address this, the group has established medium-term goals in four key areas: Carbon Neutrality, Circular Economy, Water Neutrality, and Biodiversity. For carbon neutrality, the Otsuka group aims to achieve a 50% reduction in CO<sub>2</sub> emissions by 2028 compared to 2017 levels, while also ensuring that 20% of its energy usage consist of self-generated renewable energy.

[Carbon Neutrality > Environment > Sustainability > Otsuka Holdings Co., Ltd.](#)

Taiho Pharmaceutical is working hard to help achieve these medium-term goals by building solar generation facilities, adopting carbon-neutral electricity and other renewable energy sources, and optimizing energy efficiency in its operations.

[Carbon Neutrality > Initiatives for the Environment > Taiho Pharmaceutical Co., Ltd \(in Japanese\)](#)